A novel small molecule inhibitor of inactive and active forms of oncogenic mutant KRAS promotes tumor regression in KRASmutated cancer models

被引：0
|
作者：
Weaver, D. [1 ]
Lou, Y. [2 ]
Xu, Z. [3 ]
机构：
[1] 280Bio, Exec, San Francisco, CA USA
[2] Yingli Pharma, Res, Shanghai, Peoples R China
[3] Yingli Pharma, Exec, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB091
引用
收藏
页码：S43 / S44
页数：2
相关论文
共 50 条
  • [1] A novel small molecule inhibitor of PARG, YL-18319, promotes tumor regression in BRCAmutated, Homologous Recombination Deficient, and PARP-inhibitor resistant cancer models
    Weaver, D.
    Lou, Y.
    Wild, R.
    Johnson, M.
    Xu, Z.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S135 - S135
  • [2] Selective targeting of KRAS mutant cancer cells by a novel small molecule compound
    Iskandar, Kartini
    Rezlan, Majidah
    Yadav, Sanjiv K.
    Pervaiz, Shazib
    CANCER RESEARCH, 2014, 74 (19)
  • [3] Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden
    Salehi-Rad, Ramin
    Li, Rui
    Tran, Linh M.
    Lim, Raymond J.
    Abascal, Jensen
    Momcilovic, Milica
    Park, Stacy J.
    Ong, Stephanie L.
    Shabihkhani, Maryam
    Huang, Zi Ling
    Paul, Manash
    Shackelford, David B.
    Krysan, Kostyantyn
    Liu, Bin
    Dubinett, Steven M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2389 - 2400
  • [4] Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden
    Ramin Salehi-Rad
    Rui Li
    Linh M. Tran
    Raymond J. Lim
    Jensen Abascal
    Milica Momcilovic
    Stacy J. Park
    Stephanie L. Ong
    Maryam Shabihkhani
    Zi Ling Huang
    Manash Paul
    David B. Shackelford
    Kostyantyn Krysan
    Bin Liu
    Steven M. Dubinett
    Cancer Immunology, Immunotherapy, 2021, 70 : 2389 - 2400
  • [5] Targeting KRAS mutant non-small cell lung cancer (NSCLC) with deltarasin: A small molecule inhibitor of KRAS-PDEδ interaction.
    Zhang, Jun
    Xu, Ke
    Shin, Dong Moon
    Deng, Xingming
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells
    Wallis, Nadav
    Oberman, Froma
    Shurrush, Khriesto
    Germain, Nicolas
    Greenwald, Gila
    Gershon, Tehila
    Pearl, Talia
    Abis, Giancarlo
    Singh, Vikash
    Singh, Amandeep
    Sharma, Arun K.
    Barr, Haim M.
    Ramos, Andres
    Spiegelman, Vladimir S.
    Yisraeli, Joel K.
    RNA BIOLOGY, 2022, 19 (01) : 26 - 43
  • [7] Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor
    Christensen, James G.
    Fell, Jay B.
    Marx, Matthew A.
    Fischer, John
    Hallin, Jill
    Calinisan, Andrew
    Baer, Brian
    Burkhard, Michael
    Blake, James
    Vigers, Guy
    Aranda, Ruth
    Hargis, Lauren
    Briere, David
    Engstrom, Lars
    Olson, Peter
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor gene
    Sangodkar, Jaya
    Mazhar, Sahar
    Wiredja, Danica
    Gokulrangan, Giridharan
    Schlatzer, Daniela
    Kastrinsky, David
    Difeo, Analisa
    Yao, Shen
    Izadmehr, Sudeh
    Sharma, Neelesh
    Ioannou, Yiannis
    Ohlmeyer, Michael
    Narla, Goutham
    MOLECULAR CANCER RESEARCH, 2014, 12
  • [9] Anti-tumor activity of a TBK1/IKBKE inhibitor in combination with a MEK inhibitor in KRAS mutant colorectal and non-small cell lung cancer models
    Stinson, S.
    He, J.
    Hollenback, D.
    Jia, J.
    Kaplan, J.
    Venkataramani, C.
    Babusis, D.
    Guevara, F.
    Nelson, T.
    Cavanaugh, J.
    Asahina, H.
    Ray, A.
    Sicinska, E.
    Fuchs, C.
    Barbie, D.
    Wong, K. K.
    Ng, K.
    Dornan, D.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S146 - S146
  • [10] Combination of the novel ERK inhibitor AZD0364 with the MEK inhibitor selumetinib significantly enhances antitumor activity in KRAS mutant tumor models
    Flemington, Vikki
    Simpson, Iain
    Breed, Jason
    Davies, Emma
    Gibbons, Francis
    Hopcroft, Phillip
    Lyndsay, Nicola
    Jones, Christopher
    Jones, Clifford
    Robinson, David
    Rooney, Claire
    Roberts, Karen
    Sandin, Linda
    Ward, Richard
    Zhang, Pei
    Pease, Elizabeth
    CANCER RESEARCH, 2018, 78 (13)
12345